Highlights of This Issue 937

SPECIAL FEATURES

CCR 20th Anniversary Commentary

939  CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
      Beverly A. Teicher and Kenneth C. Anderson

942  CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
      Clint T. Allen, Barbara Conley, John B. Sunwoo, and Carter Van Waes

CCR Translations

944  Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
      Roxana S. Dronca and Haidong Dong
      See related articles, p. 1115 and p. 1127

947  Moving from Evaluation to Value in Cancer Care
      Richard L. Schilsky
      See related article, p. 1036

CCR Perspectives in Drug Approval

950  FDA Approval: Siltuximab for the Treatment of Multicentric Castleman Disease
      Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock,
      Nitin Mehrotra, Pedro Del Valle, Haelah Saber, Christopher Sheth, Brenda Gehrze, Robert Justice,
      Ann Farrell, and Richard Pazdur

Molecular Pathways

955  Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
      Rebecca A. Prewis, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood

962  Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
      Hae-Yun Jung, Laurent Fattet, and Jing Yang

Reviews

969  Zebrafish: A New Companion for Translational Research in Oncology
      Jorge Barriuso, Raghavendra Nagaraju, and Adam Hurlstone

976  Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
      Valsamo K. Anagnostiou and Julie R. Brahmer

CANCER THERAPY: CLINICAL

985  A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
      Guillermo Garcia-Manero, Hanna J. Khoury, Elias Jabbour, Jeffrey Lancer, Shannon L. Winski,
      LouAnn Cable, Selena Rush, Lara Maloney, Grant Hogeland, Mieke Paszynski,
      Monica Cabrero Calvo, Zach Bohannan, Alan List, Hapop Kantarjian, and Rami Komrokij

995  CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
      Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gamlich, Maryann Gallagher,
      Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer,
      Noah Goodman, Susan Domschek, Kerrihi Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer

1002  Phase I Dose-escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
      Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo,
      David F. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart,
      Lee S. Rosen, and Daniel W. Bowles

1010  Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
      Matthias Piesche, Vincent T. Ho, HaeSook Kim, Yukoh Nakazaki, Michael Nehil, Nasser K. Yaghi,
      Dmitriy Kolodin, Jeremy Weiser, Peter Altuvog, Helena Kiefel, Edwin P. Alyea, Joseph H. Antin,
      Corey Cutler, John Koreth, Christine Canning, Jerome Ritz, Robert J. Soiffer, and Glenn Dranoff
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, and Steven A. Rosenberg

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, and Lori J. Wirth

Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
Alberto F. Sobrero, Alessandro Pastorino, Daniel J. Sargent, and Paolo Bruzzi

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, and Anthony B. El-Khoueiry

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy
Szeman Ruby Chan, Amy M. Fowler, Julie A. Allen, Dong Zhou, Carmen S. Dence, Terry L. Sharp, Nicole M. Fettig, Farrokh Dehdashti, and John A. Katzenellenbogen

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri, David J. Figueiredo, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Stephanie M. Cushman, Chen Jiang, Ace I. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouroos Owzar, Herbert I. Hurwitz, and Andrew B. Nixon

Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Pierre Laurent-Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez-Toralla, Rachel Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, Theyy Hor, Zakaria El Harrak, Xinyu Li, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, and Valerie Taly

Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Kristan Meetze, Sylvie Vincent, Steven Tyler, Elizabeth K. Maza, Andrea R. Delpeso, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Sally Weiler, Bin Feng, Jeno Gyuris, and Zhigang Weng

The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Sara M. Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furehring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tøtterman, and Peter Ellmark

See related commentary, p. 944

Table of Contents
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1127</td>
<td>Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies</td>
<td>Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom</td>
</tr>
<tr>
<td>1139</td>
<td>Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing’s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression</td>
<td>Min H. Kang, Jing Wang, Monish R. Makeva, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. T. Triche, and C. Patrick Reynolds</td>
</tr>
<tr>
<td>1161</td>
<td>Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin</td>
<td>Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde I.A. Adekola, Ira Wati Kandela, Changrong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam</td>
</tr>
<tr>
<td>1172</td>
<td>Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy</td>
<td>Hyun Jung Cho, Hye Jin Song, Da Eun Jeong, Yun Je Seo, Sang Shin, Je Gun Juong, Yong Jun Kwon, Yoon La Choi, Woong Yang Park, Hyun Moo Lee, Ho Jun Seol, Young Mog Shim, Kyeung Min Joo, and Do Hyun Nam</td>
</tr>
<tr>
<td>1183</td>
<td>Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma</td>
<td>Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zhonghua Niu, Song Liu, Ben Wang, Qi Sun, Weibo Niu, Enyu Liu, Bayong Wang, and Jun Niu</td>
</tr>
</tbody>
</table>

### BIOLOGY OF HUMAN TUMORS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1196</td>
<td>Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer</td>
<td>Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Munneer, Stephan Beck, and John D. Kelly</td>
</tr>
<tr>
<td>1207</td>
<td>A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients</td>
<td>Kristine Kleivi Sahlberg, Giulia Bottai, Bjorn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Bertelsen-Dale, and Libero Santarpia</td>
</tr>
<tr>
<td>1225</td>
<td>Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer</td>
<td>Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinli Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lu Tao, and Chuanxin Wang</td>
</tr>
</tbody>
</table>

---

**AC icon indicates Author Choice**

**CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org**

For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.
Clinical Cancer Research

21 (5)


Updated version
Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/21/5

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.